Aimmune Therapeutics (AIMT): Expecting Success In Palisades Trial - Piper Jaffray

August 23, 2016 6:50 AM EDT
Get Alerts AIMT Hot Sheet
Price: $16.28 -0.91%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 25 | Down: 28 | New: 8
Trade AIMT Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Aimmune Therapeutics (NASDAQ: AIMT) after the company hosted a call with Dr. Vickery, lead author of the recently published academic DEVIL study of OIT for peanut allergy in very young children.

DEVIL demonstrated high levels of sustained unresponsiveness to peanut even after OIT withdrawal, suggesting clinically meaningful protection and perhaps even a disease modifying effect, combined with “unexpectedly good” tolerability. The analyst believes these encouraging results are supportive of the potential differentiation of OIT (vs subcutaneous & epicutaneous methods) for desensitization and perhaps disease course modification, which Aimmune’s AR101 can bring to the larger peanut allergy market.

The analyst stated "we also sees the DEVIL results as reinforcing his conviction in the design and high probability of success of the PALISADE trial, as well as AR101 study in young children during 2017. In advance of PALISADE enrollment completion expected during 2H16, we continue to see clear advantages of OIT and AR101 versus other approaches to peanut allergy".

No change to the price target of $38.

For an analyst ratings summary and ratings history on Aimmune Therapeutics click here. For more ratings news on Aimmune Therapeutics click here.

Shares of Aimmune Therapeutics closed at $14.93 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Piper Jaffray, Charles Duncan

Add Your Comment